Why Emotional Health Must Be Part of
Survivorship Care
Co-Written by Dr. Barbara Bartlik and Dr. Robert L. Bard
Cancer care has traditionally focused on surgery, chemotherapy, radiation,
medications, and imaging. Yet one of the most powerful influences on health
outcomes often receives far less attention: stress. According to integrative
psychiatrist Dr. Barbara Bartlik and
diagnostic imaging specialist Dr. Robert L. Bard,
chronic stress and anxiety are not merely emotional burdens—they can become
biological burdens that affect healing, immune resilience, inflammation, sleep
quality, and quality of life.
Their message is clear: no cancer treatment plan is complete unless it
addresses the mind and body together.
Understanding
the Stress Response
Stress is the body’s natural alarm
system. In short bursts, it can be useful. It helps us react to danger, sharpen
focus, and mobilize energy. But when stress becomes chronic—as it often does
during diagnosis, treatment, financial strain, uncertainty, or fear of
recurrence—the body can remain trapped in a constant state of physiological
alert.
This prolonged stress response activates the adrenal glands, which release
cortisol and adrenaline. These hormones are helpful during emergencies, but
harmful when elevated for long periods.
Persistently high cortisol has been associated with:
Suppressed immune
surveillance
Increased inflammation
Sleep disruption
Insulin resistance
Weight gain or muscle loss
Mood instability
Fatigue and burnout
Impaired tissue repair
For someone navigating cancer or survivorship, these effects can be
especially significant.
Stress
and the Immune System
The immune system plays a central
role in monitoring abnormal cells, fighting infection, and assisting recovery
after treatment. Chronic anxiety may weaken this system by altering white blood
cell function, inflammatory signaling, and restorative sleep cycles.
Dr. Bartlik emphasizes that emotional trauma, unresolved fear, depression,
and persistent hypervigilance can keep the nervous system in “fight-or-flight”
mode. When the body never fully returns to calm, healing resources are diverted
away from restoration.
This does not mean stress “causes cancer” in a simplistic
sense. Cancer is complex and multifactorial. Genetics, environment, lifestyle,
exposures, hormones, and age all matter. However, unmanaged stress can
aggravate biological terrain, worsen symptoms, and diminish the body’s ability
to recover optimally.
Cortisol,
Inflammation, and Disease Burden
Inflammation is one of the most
discussed pathways in modern medicine. While acute inflammation helps healing,
chronic inflammation may contribute to pain, metabolic dysfunction, vascular
strain, mood disorders, and fatigue.
Stress hormones can intensify inflammatory cascades. Survivors often
describe feeling “wired but tired”—an exhausted state marked by anxiety, poor
sleep, racing thoughts, and low resilience. This is where psychiatry, lifestyle
medicine, and rehabilitation can become powerful allies.
Dr. Bartlik advocates a whole-person approach that may include:
Nutritional support
Sleep restoration
Mindfulness and breathing
practices
Trauma-informed therapy
Exercise prescriptions
Nutraceutical support when
appropriate
Medication when clinically
indicated
Social connection and
purpose-building
The
Cancer Diagnosis Itself Is a Stress Event
A cancer diagnosis is not only a
medical event—it is a psychological earthquake. Even patients with excellent
prognoses may experience panic, grief, anger, isolation, or catastrophic
thinking. During treatment, many face body-image changes, pain, financial
pressure, career uncertainty, and family strain.
After treatment ends, many expect life to return to normal. Instead,
survivorship often brings a new challenge: silent anxiety. Fear of recurrence,
ongoing fatigue, hormonal shifts, cognitive fog, and loss of confidence can
linger for years.
This is where post-treatment rehabilitation becomes essential.
Survivorship
Is More Than “Cancer-Free”
Dr.
Robert L. Bard has long advocated that survivorship should not be
measured only by whether visible disease is gone. It should also be measured by
how the patient functions physically, mentally, hormonally, socially, and
emotionally.
He argues that many survivors are declared “finished” with treatment while
still struggling with:
Chronic fatigue
Lymphedema
Neuropathy
Brain fog
Anxiety and depression
Loss of strength
Sleep disorders
Pain syndromes
Hormonal imbalance
Deconditioning
Fear of movement
These are rehabilitation issues—and they deserve clinical attention.
How
Rehabilitation Reduces Stress Biology
Cancer rehabilitation is one of the
most underutilized tools for stress reduction. When survivors regain function,
movement, strength, and confidence, the nervous system often shifts out of
chronic threat mode.
Dr. Bard supports multidisciplinary survivorship rehab that may include:
Physical therapy
Strength training
Balance and fall-prevention
work
Lymphedema therapy
Massage and myofascial care
Cognitive rehabilitation
Nutritional counseling
Integrative psychiatry
Sleep medicine
Mind-body coaching
Movement itself can be medicine. Exercise has been shown to support mood
regulation, insulin sensitivity, sleep quality, circulation, and inflammatory
balance. Even walking programs, resistance bands, yoga, tai chi, or supervised
recovery exercise can create profound gains.
Imaging,
Insight, and Personalized Recovery
As a diagnostic imaging specialist,
Dr. Bard emphasizes that recovery should be personalized, not generic. Advanced
imaging can help identify inflammation, vascular compromise, musculoskeletal
strain, scar tissue behavior, or other treatable contributors to pain and
dysfunction.
When patients understand why they hurt or where
limitations exist, anxiety often decreases. Information reduces fear. Objective
findings can guide smarter rehabilitation plans and provide measurable progress
markers.
The
Emotional Side of Healing
Dr. Bartlik notes that healing
requires safety. Patients who feel heard, supported, and empowered often do
better emotionally than those who feel dismissed or rushed. Compassionate
medicine lowers stress. Human connection matters.
Support groups, counseling, spiritual care, journaling, creative arts, and
relationship repair can all become part of survivorship medicine. There is no
single path—but there should always be a path.
A
New Standard of Care
Stress and anxiety should no longer
be considered side issues in oncology. They are central variables affecting
resilience, adherence, sleep, inflammation, mood, and recovery capacity. The
future of cancer care is integrated care—where oncologists, imaging
specialists, psychiatrists, rehab teams, nutrition experts, and exercise
professionals work together.
As Drs. Bartlik and Bard would agree: surviving cancer is not the finish
line. Restoring peace, strength, confidence, and quality of life is where the
next chapter begins.
The Hidden Employment Crisis Potentially Facing Cancer Patients
A Social Commentary By: Lennard M. Goetze, Ed.D / Barbara Bartlik, MD
Disclaimer: This commentary does not suggest that employers openly terminate workers because they have cancer. In most cases, employment actions are tied to broader issues such as prolonged absences, repeated medical leave, reduced availability, performance disruption, staffing pressures, or disputes over accommodations during treatment. However, as reports and legal complaints continue to surface, serious illness—particularly cancer requiring extensive time away from work—can place employees in a vulnerable position where their job security may be jeopardized. This social commentary examines that growing concern: the intersection of health hardship, workplace pressures, and the need for fairer protections for individuals managing life-threatening disease while trying to remain employed.
Cancer
changes everything in a moment. It alters health, finances, family dynamics,
and emotional stability. Yet for many patients, another crisis quietly emerges
after diagnosis: the fear of losing their job. While public conversations often
focus on treatment and survival, far less attention is given to employment
vulnerability—the growing pattern of workers being sidelined, pressured out, or
terminated after serious illness.
Advocates
describe it as one of the most overlooked burdens of cancer care. Four-time
cancer survivor and patient advocate SCOTT BAKER has seen it firsthand. Through
years of supporting patients and families, he says many workers discover that
the moment they need compassion most is when job security becomes uncertain.
“There
are certain businesses where it’s just too much time off,” Baker explained.
“They need you to be a ten out of ten every day, so they say, we can’t keep
you.” This is not simply an HR issue. It
is a public health concern, an economic concern, and increasingly, a legislative
concern.
The
Unspoken Pattern of Employment Risk
Many workers assume that once
diagnosed with cancer, legal systems automatically shield them from
termination. The reality is more complicated. Some protections exist under
disability and leave laws, but they are often narrow, time-limited, or
dependent on company size, job tenure, and documentation requirements. That
leaves countless employees exposed.
Baker
recalled cases involving young nurses who had been employed for less than a
year when they were diagnosed. Because they had not yet qualified for leave
protections, they were let go. “They didn’t qualify for FMLA, so they just let
them go,” he said.
Healthcare
workers themselves are not immune. In fact, Baker emphasized that hospitals and
medical institutions can reflect the same pressures seen in other
industries—staffing shortages, productivity demands, and limited tolerance for
extended absence. For patients, the message can feel brutal: get well quickly,
or become replaceable.
Even
After Treatment, the Battle Continues
One of the least understood
realities of cancer recovery is that treatment completion does not equal full
recovery. Many survivors return to work carrying fatigue, neuropathy, cognitive
fog, anxiety, chronic pain, or emotional trauma. “They come back, and they’re
not the same,” Baker noted. “It takes a long time to recover.”
This
creates a dangerous gap. Employers may expect immediate peak performance, while
survivors are still rebuilding physically and mentally. In fast-paced or
high-output environments, workers may be quietly managed out, demoted, or
judged against pre-illness standards. The result is a second trauma layered on
top of the first.
The
Self-Employed Face a Different Crisis
For entrepreneurs, freelancers, and
small business owners, illness can be even more devastating. There may be no
paid leave, no corporate benefits, and no substitute income stream. “They go
from breadwinner to no bread,” Baker said bluntly. This group often falls through policy cracks.
They are workers without the protections many traditional employees assume
exist.
What
Can Be Done Legislatively?
Advocates increasingly argue that
cancer survivorship must include employment security. Several reforms could
make a meaningful difference:
1. Expand Medical Leave Eligibility: Current leave laws often exclude newer employees, part-time
workers, or workers in smaller companies. Reform should shorten waiting periods
and broaden eligibility for serious illness.
2. Modernize Temporary Disability Benefits: Baker recently advocated for reform of temporary disability
insurance, noting that some benefit levels remain shockingly outdated. “$189 a
week is not cutting it,” he said. For many families, that amount would not
cover transportation to treatment, let alone rent or groceries.
3. Protect Return-to-Work Rights: Legislation could require reasonable phased returns,
flexible scheduling, and medical accommodation for cancer survivors re-entering
the workforce.
4. Strengthen Anti-Retaliation Enforcement: Some workers are not formally fired—they are squeezed out
through reduced hours, negative reviews, or hostility after disclosure. Better
enforcement mechanisms are urgently needed.
5. Incentivize Retention: Tax
credits or subsidies for employers who retain and accommodate workers
undergoing treatment could turn compassion into practical policy.
Work-Arounds
for Workers Right Now
Until laws catch up, patients need strategies:
·Disclose medical issues carefully
and document all communications.
·Request accommodations in writing.
·Understand leave rights under
federal and state law.
·Consult employment attorneys or
patient advocacy groups early.
·Build relationships with supervisors
who may advocate internally.
Baker
credits a supportive supervisor with helping save his own position during
prolonged treatment. Without that ally, the outcome may have been very
different. That should not depend on
luck.
A
Larger Moral Question
How a society treats workers during
illness reveals its values. Cancer patients are not disposable assets. They are
teachers, nurses, tradespeople, executives, parents, veterans, and community
members fighting for their lives. To punish illness with unemployment is not
efficiency—it is failure.
Conclusion
The hidden employment crisis facing
cancer patients deserves national attention. Behind many survival stories lies
another story of lost income, lost dignity, and preventable hardship. The goal
of modern medicine is not merely to keep people alive—it is to preserve their
ability to live.
Scott
Baker’s warning is clear: the risk is real, widespread, and often invisible.
The next frontier of survivorship is not only better treatment. It is better
protection. No one battling cancer should also have to battle for the right to
keep their job.
PART 2: CLINICAL PERSPECTIVE
WORK IS
MEDICINE: WHY A CANCER DIAGNOSIS SHOULD NOT END A PERSON’S CAREER
Written by Dr. Robert L.
Bard
I have spent my professional life studying disease through imaging,
diagnostics, and the realities of patient care. Over decades of working with
cancer patients, I have learned one truth that too many employers fail to
understand: a cancer diagnosis does not automatically mean disability,
incapacity, or the end of productivity.
That is why I stand in full support of the
concerns raised by Scott Baker in his
important discussion about workers being fired because of cancer. This issue is
real, it is harmful, and in many cases, it is based on fear rather than fact.
Too often, people are judged by a diagnosis instead of their actual condition,
their strength, or their ability to contribute. As physicians, employers, and
as a society, we must do better.
The Diagnosis Is Not the Disability
One
of the greatest misconceptions in the workplace is the belief that once a
person hears the word “cancer,” they are no longer able to function. This is
medically inaccurate. Many cancers today are treatable, manageable,
slow-growing, or responsive to therapy. Some remain stable for years or
decades.
I have personally followed patients with
low-grade prostate cancer who continue to live normal, active, productive
lives. With modern imaging, surveillance, and appropriate care, we can often
confirm that their condition has not progressed and does not impair their daily
function.
I have also known patients with metastatic
disease who still climb stairs, go to work, care for families, and remain
deeply engaged in life. Their diagnosis did not define their usefulness. Their
resilience did.
Work Can Be Healing
Employment
is not only about income. Work gives structure, purpose, identity, dignity, and
hope. For many patients, returning to work or continuing to work becomes part
of recovery. It restores normalcy during a frightening time. It reminds them
they are still needed.
I recall experiencing severe postoperative
pain years ago after a dental procedure. The discomfort was so intense that I
went back to work simply to focus my mind on something productive rather than
on suffering. That experience taught me that meaningful activity can help
redirect pain, anxiety, and despair. Cancer patients deserve that same opportunity.
The Role of Medical Verification
Today
we have advanced tools that can help objectively assess a patient’s status.
Through ultrasound imaging, Doppler flow studies, elastography, and other
noninvasive technologies, we can monitor tumor behavior, treatment response,
and physical function.
This means decisions about employment should
not be based on assumptions or stigma. They should be based on facts. If a
patient is medically capable of working, physicians should feel empowered to
document that reality. Employers should welcome that guidance rather than fear
it.
A Special Concern: Healthcare Workers
I was
especially troubled to hear reports of nurses and healthcare workers losing
jobs soon after a diagnosis. That is not only unjust—it is counterproductive.
When a nurse with cancer continues to serve
with strength and professionalism, it sends a powerful message to every patient
in that hospital: survival is possible, life continues, and illness does not
erase value. Those workers become living symbols of courage. To remove them
because “it doesn’t look good” is a failure of compassion and leadership.
Final Word
A
cancer diagnosis should trigger support, not suspicion. It should lead to
accommodation where needed, not automatic termination. We need stronger
workplace protections, physician-backed return-to-work pathways, and a national
understanding that many people with cancer can continue to live and work
successfully.
Cancer
is a health challenge. It should never become an employment sentence.
NEWS REFERENCES:
1. United Airlines Employee Claims He Was Fired Mid-Chemo Session: A United Airlines worker with stage 4 lymphoma alleged he was fired over the phone during chemotherapy for “taking too much time off work.” Read People Magazine Report
2. Independent Report on Same United Airlines Lawsuit: Detailed coverage of the federal complaint, including allegations he continued working while undergoing treatment. Read The Independent Report
3. Black Enterprise Coverage: Fired After Using PTO for Chemotherapy: Follow-up reporting focused on the use of accrued leave for cancer treatment and alleged termination. Read Black Enterprise Report
4. Nurse Alleges Firing While Fighting Breast Cancer: Public reporting described a nurse claiming termination after requesting leave connected to surgery and treatment. (Referenced in prior public reports.) Search Related Public Coverage
5. Workers Losing Jobs Before FMLA Eligibility: The United complaint alleges termination one week before the employee qualified for federal protected leave. Read FMLA Allegation Details
6. National Pattern: Cancer Patients Reporting Employment Retaliation- This case has drawn public attention because it reflects a broader pattern of workers claiming punishment after serious diagnoses. Read National Discussion Coverage
7. Lawsuit Includes ADA Disability Discrimination Claims: The complaint reportedly includes violations under the Equal Employment Opportunity Commission framework and disability law standards. Read Legal Allegations
8. “No One Should Have to Choose Between Health and Livelihood”: The employee’s attorney framed the case as forcing workers to choose between treatment and employment. Read Attorney Statement
Male Breast Cancer Global Alliance Honors Two
Champions of Survivorship, Advocacy and Recovery
In a spirited and highly meaningful
leadership meeting, the Male Breast Cancer Global
Alliance (MBCGA) formally recognized two distinguished men whose lives
and work embody courage, compassion, and action in the cancer survivorship
movement: Scott Baker and Dr. Jay Harness.
Hosted by MBCGA President and CEO Cheri Ambrose, the virtual gathering brought
together voices from medicine, publishing, advocacy, and survivorship to
celebrate the appointments of these two men into key leadership roles. Lennard Goetze moderated the event, while
emphasizing a new and growing mission: the launch of a broader movement focused
on Male Breast Cancer Rehabilitation and Restorative Care.
Leadership
Appointments Rooted in Service
The meeting opened with Cheri
Ambrose announcing that Dr. Harness had been invited to join the MBCGA Medical
Advisory Board, an invitation he warmly accepted. His decades of
surgical oncology leadership, global reputation, and groundbreaking advocacy
for exercise oncology made him an ideal addition to the organization’s
expanding medical team.
Soon after, Scott Baker was
officially invited to serve as Community Outreach Ambassador,
recognizing his tireless grassroots support of patients, survivors, and
families navigating the cancer journey. Baker also received notice of a special
award to be presented later in the season for his humanitarian volunteerism and
bedside advocacy.“These appointments
are based on merit, achievements, and proven volunteerism,” Ambrose noted. “We
need leaders who understand survivorship not only professionally—but
personally.”
Nomination
of 2026 Leaders in Survivorship
Though unable to attend the meeting
because of active patient-care responsibilities, Dr.
Robert Bard was repeatedly acknowledged as the principal force behind
the nomination of both honorees. Even in his absence, his presence was strongly
felt throughout the discussion, as speakers referenced his judgment,
leadership, and unwavering commitment to advancing survivorship through
meaningful action. Those who know Bard understand that he does not offer
endorsements casually. When he supports an individual for leadership, it is
rooted in observed merit, measurable contribution, and a genuine belief that
the person can elevate the mission.
Lennard Goetze explained that Bard “hands down” championed the appointment
of Dr. Jay Harness to the Medical Advisory
Board. Bard recognized in Dr. Harness not only an accomplished surgeon and
respected international authority, but also a physician who has continued to
serve long after retirement through education, mentorship, and public advocacy.
In particular, Bard admired Harness’s tireless promotion of exercise oncology—a
field transforming how clinicians view movement, strength, and rehabilitation
during the cancer journey. To Bard, this was not simply a wellness topic; it
was an essential component of modern survivorship medicine.
At the same time, Bard strongly supported the induction of Scott Baker into a leadership role in community
outreach. Baker’s value, in Bard’s eyes, comes from something no credential
alone can provide: lived experience forged through repeated battles with
cancer. Bard has long respected survivors who turn pain into purpose, and
Baker’s willingness to guide others, encourage patients, and stand beside those
in fear represented exactly the kind of servant leadership the organization
seeks. His compassion is practical, credible, and deeply human.
Together, these nominations reveal Bard’s broader philosophy of care. He
believes the future of oncology must go beyond removing tumors or completing
treatment protocols. True victory includes helping patients reclaim strength,
dignity, confidence, mobility, emotional stability, and hope. In Dr. Harness,
Bard saw the science and strategy of survivorship. In Scott Baker, he saw the
heart and humanity of survivorship. By advancing both men, Bard effectively
endorsed a new model of cancer leadership—one where medicine and mentorship
stand side by side, and where quality of life is recognized as the next
frontier of healing.
ExerciseOncologyTakesCenter Stage
One of the most compelling and
forward-looking themes of the meeting was the rising importance of exercise
oncology—a rapidly expanding discipline grounded in scientific
evidence that uses movement, resistance training, cardiovascular conditioning,
and guided physical activity to improve outcomes for people living with and
recovering from cancer. What was once dismissed as a secondary lifestyle
suggestion is now being recognized as an essential pillar of supportive cancer
care. Throughout the discussion, participants made it clear that survivorship
cannot be fully addressed without confronting the physical decline, fatigue,
weakness, emotional strain, and loss of function that so often follow diagnosis
and treatment.
At the center of this conversation was Dr. Jay
Harness, who spoke with conviction about more than thirty years of
accumulating research demonstrating that exercise can positively influence
clinical outcomes across multiple cancer populations. His remarks reflected
both scientific authority and practical wisdom. He emphasized that the data are
no longer speculative or fringe. Study after study has shown that properly
guided exercise can improve stamina, preserve lean muscle mass, reduce
treatment-related fatigue, enhance emotional well-being, support metabolic
health, and help many patients tolerate therapies more effectively.
“Exercise is medicine,” he stated. That phrase became one of the defining
messages of the meeting. Dr. Harness explained that movement creates a cascade
of beneficial physiologic responses throughout the body. Exercise can stimulate
immune surveillance, improve circulation, enhance oxygen delivery to tissues,
and support glucose regulation and insulin sensitivity. It can help counter the
deconditioning that often accompanies chemotherapy, radiation, surgery,
hormonal therapy, or prolonged inactivity. In many ways, it represents a
therapeutic intervention hiding in plain sight.
He further noted that the benefits are not only muscular or cardiovascular.
Physical activity activates powerful neurochemical responses that can directly
influence morale and mental health. Endorphins, dopamine, serotonin, and other
so-called “happy hormones” can elevate mood, reduce anxiety, and restore a
sense of motivation at a time when many survivors feel emotionally depleted.
Yet Dr. Harness stressed that these feel-good effects are only one part of a much
larger biological story. Exercise also impacts inflammatory pathways, cellular
signaling systems, mitochondrial efficiency, and other mechanisms linked to
healing, resilience, and recovery.
As founder of Cancer Fitness, Dr.
Harness has become an influential voice helping patients, clinicians, and
advocacy groups rethink what rehabilitation can look like after cancer. His
mission is not simply to encourage people to move more—it is to help integrate
structured, intelligent movement into the cancer care continuum itself.
The meeting made one point unmistakably clear: exercise is no longer an
optional side note in survivorship. It is becoming a frontline strategy for
restoring strength, confidence, independence, and quality of life.
Scott
Baker: Survivor Wisdom with Real-World Truth
If Dr. Harness represented the
scientific case for survivorship movement, Scott Baker represented the human
case. A four-time cancer survivor, Baker spoke candidly about the emotional
barriers many men face when illness strips away independence.
“There’s nothing wrong with asking
for help,” he said. “It doesn’t make you weak.” He noted that many men avoid
support groups, rehab programs, and public discussion because they wrongly
associate vulnerability with weakness. Yet his own journey taught him that
healing begins when pride ends.
One of the most memorable lines of
the meeting came when Baker said: “It’s hard to be macho when you’re walking
around in a backless hospital gown.” The comment brought laughter—but also
truth. Cancer humbles everyone. Baker’s honesty and humor illustrated exactly
why MBCGA leaders saw him as a model spokesperson for men who need permission
to seek support.
Challenging
Bias Around Male Breast Cancer
Another major topic was the ongoing
stigma surrounding male breast cancer itself. Goetze emphasized that male
breast cancer remains underdiagnosed partly because many men do not want to
acknowledge symptoms, undergo screening, or publicly discuss a disease
culturally labeled as female.
“Stop the bias” has become a
rallying message for MBCGA. The organization believes earlier detection, public
education, and open conversations can save lives. Baker and Harness were
praised as the kind of visible male leaders who can help dismantle silence and
embarrassment.
A
New Movement: Rehabilitation and Restoration
Goetze also introduced a new
strategic segment under the MBCGA umbrella: Male Breast Cancer Rehab
and Restorative Movement. This initiative promotes a broader
understanding of survivorship—not merely living after treatment, but living
well after treatment. That means attention to:
strength
rebuilding
fatigue
recovery
emotional
resilience
body
confidence
hormonal
health
social
connection
exercise
programming
return
to purpose and identity
As Ambrose said during the
discussion, many survivors are searching for “some sense of normal”—even if it
becomes a “new normal.”
A
Global Future
Dr. Harness also accepted an
invitation to speak at the MBCGA Global Medical Summit this October, further
strengthening ties between the alliance and the worldwide exercise oncology
movement. Participants discussed future podcasts, publishing collaborations,
firefighter outreach programs, advocacy campaigns, and cross-promotional
education that can bring survivorship tools to more people internationally.
Conclusion
This was more than an appointment
meeting—it was a declaration of direction. By inducting Scott Baker and Dr. Jay
Harness into leadership, the Male Breast Cancer Global Alliance signaled that
the future of cancer advocacy must include not only awareness and treatment—but
rehabilitation, exercise, emotional healing, and restored quality of life. Two
men were honored. But countless survivors stand to benefit.
Beyond Survival A Cardiologist’s Perspective with Dr. Hwaida Hannoush
By: Lennard Goetze, Ed.D | Daniel Root | Regina Bessler, PhD
In an era when medicine is becoming increasingly specialized, few physicians
are as committed to bridging disciplines as Dr. Hwaida Hannoush, a cardiologist and functional
medicine practitioner whose work reflects the growing need for more
personalized, predictive, and preventive care. As the founder of Precimed Clinic, Dr. Hannoush
has built her clinical philosophy around one central belief: that precision medicine must be at the heart of
modern healthcare.
With a strong focus on women’s
heart health, preventive cardiology, and individualized
treatment strategies, Dr. Hannoush combines the rigor of traditional
cardiovascular medicine with the systems-based insight of functional medicine.
Her approach is rooted in uncovering the deeper drivers of disease rather than
simply managing symptoms. At Precimed Clinic, that means using advanced
diagnostics, nuanced interpretation, and personalized care plans to help
patients understand the “why” behind their cardiovascular risk—and, where possible,
reverse it.
But in a recent discussion about cancer rehabilitation and survivorship, Dr.
Hannoush turned her attention to a topic that remains dangerously
under-recognized in mainstream medicine: the cardiovascular consequences of cancer therapy. Her
message was clear, urgent, and clinically significant: for many cancer survivors, the battle does
not end when the tumor is gone.
The Overlooked Crisis in
Cancer Survivorship
Much of the public conversation around cancer treatment centers on
remission, recurrence, and tumor response. But according to Dr. Hannoush, there
is another threat quietly affecting survivors long after treatment has ended: cardiovascular injury. “I want to highlight,” she said, “that for
many cancer survivors, cardiovascular side effects of chemotherapy become a
serious — and often unrecognized — long-term threat.” That observation reframes
the survivorship conversation in an important way.
While cancer therapies are often life-saving, many of them can place
profound stress on the cardiovascular system. These effects may not always be
immediately visible, but over time they can contribute to heart failure, arrhythmias, coronary disease,
vascular dysfunction, metabolic injury, and long-term decline in physical
resilience. Research
shows that as cancer treatments become more effective and survival extends,
cardiovascular disease increasingly emerges as a dominant competing risk —
underscoring why protecting the heart during and after cancer treatment is not
optional, but essential.
This is the domain of cardio-oncology,
an evolving field focused on protecting heart health before, during, and after
cancer treatment. Dr. Hannoush has seen its importance firsthand, particularly
through her previous work evaluating heart function in patients undergoing
aggressive therapies.
She explained that this is not a fringe concern or a rare side effect. In
many cases, cardiovascular
complications become the dominant long-term health threat in cancer survivors,
particularly when these patients are not proactively monitored.What
sets Dr. Hannoush apart from many cardiologists is that she brings a second,
complementary lens to this work: functional medicine. While cardio-oncology
guidelines focus on monitoring heart function, managing cardiovascular risk
factors, and intervening when damage is detected, functional medicine asks a
deeper upstream question — why is this particular patient’s body uniquely
vulnerable, and what can be done to strengthen its resilience before and after
treatment begins? It is the integration of both frameworks that defines her
approach to survivorship care.
Why the Heart Is So
Vulnerable
One of the strengths of Dr.
Hannoush’s perspective is her ability to explain cardiac injury not as a single
event, but as a multi-layered biological
process.
According to her, chemotherapy and related treatments can harm the
cardiovascular system through several overlapping mechanisms. First, some drugs
can cause direct injury to the
myocardium, the muscular tissue of the heart itself. Others
disrupt the mitochondria,
the energy-producing structures that are especially abundant in cardiac tissue.
“The heart is rich in mitochondria,” she explained, “which is the power
source.”
When mitochondrial function is impaired, the heart may continue beating, but
it does so with reduced cellular efficiency and diminished reserve.Research
confirms that drugs like doxorubicin cause mitochondrial oxidative stress,
impaired energy production, and accelerated cell death in cardiac tissue — and
that a patient’s individual mitochondrial biology can influence how vulnerable
their heart is to this damage, pointing toward a future of more personalized
cardiac risk assessment.
Cancer treatments can also affect the coronary arteries, promoting atherosclerosis and
increasing the risk of infarction or heart attack. At the same time, they may
alter glucose regulation,
insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory
burden—all of which increase cardiovascular risk even further.
Dr. Hannoush also emphasized the role of hormonal disruption, especially in therapies that
suppress sex hormones. In both women and men, these hormonal shifts can have
significant effects on vascular function, metabolism, and heart health. And perhaps
most compellingly, she pointed to a mechanism often left out of conventional
oncology conversations: the gut-heart
axis.
“Gut dysbiosis is a very important side effect of chemotherapy,” she said.
Because gut health influences inflammation, immune regulation, neurotransmitter
production, and metabolic stability, its disruption can have ripple effects far
beyond digestion. Emerging preclinical
evidence supports this concern: chemotherapy-induced gut dysbiosis can increase
intestinal permeability, allowing bacterial products to enter the bloodstream
and drive systemic inflammation that worsens cardiovascular injury — a pathway
now being studied as part of the gut-microbiota-heart axis. While direct proof
in humans is still developing, the mechanistic evidence is compelling and
growing.
One cardiovascular risk that
deserves particular mention — especially for readers who have undergone
treatment for breast cancer, Hodgkin lymphoma, or lung cancer — is radiation
therapy. When radiation involves the chest, it can damage the coronary
arteries, heart valves, and the pericardial sac through a process of chronic
inflammation and scarring. What makes this especially difficult to detect is
that these effects can remain silent for years or even decades after treatment
ends. Long-term survivors who received chest radiation as recently as their
twenties or thirties may not see cardiovascular consequences until midlife —
making awareness and surveillance in this population critically important.
Taken together, these mechanisms reveal a difficult truth: many cancer treatments affect not only the
tumor, but the body’s foundational systems of resilience.
The Problem with Waiting
Too Long
A major concern for Dr. Hannoush is
that conventional monitoring often catches cardiovascular damage too late. Traditionally,
clinicians look for a decline in ejection fraction (EF) ― a measure of how much blood the
heart pumps out with each beat. But by the time EF drops, injury may already be
well underway.
That is why she strongly advocates strain imaging, a more sensitive technique that evaluates
subtle deformation in the heart muscle before overt dysfunction appears. “You
don’t want to wait till the heart function drops,” she explained. “You want to
detect it earlier.”
This technology, commonly referred to as longitudinal strain, has become a valuable tool in
cardio-oncology because it can reveal subclinical deterioration in the myocardium before
symptoms emerge and before standard imaging appears abnormal.
For Dr. Hannoush, this represents one of the clearest examples of what
precision medicine should look like in practice: not reactive care, but early detection, functional monitoring, and
intervention before collapse. She also emphasized that such
monitoring should not be sporadic or incidental. Oncology patients, she argued,
should have structured
cardiovascular protocols that include echocardiograms,
biomarker tracking, and ongoing surveillance tailored to their treatment
exposure.
Cancer Rehab Must Be More
Than Physical Therapy
Another central theme in Dr.
Hannoush’s discussion was the need to redefine what “rehabilitation” actually
means after cancer treatment. From her perspective, true recovery is not limited to mobility or strength
training. It must include the broader restoration of the systems that treatment
may have disrupted—the heart,
skeletal muscle, metabolism, hormones, nutrition, detoxification pathways, and
even the microbiome.
She specifically highlighted skeletal
muscle as a major but often neglected player in survivorship.
“Muscles are very important,” she said, noting that skeletal muscle functions
as a kind of metabolic organ.
It helps regulate insulin sensitivity, glucose uptake, and systemic energy
balance. When cancer treatment contributes to muscle loss or frailty, the
patient does not just become weaker—they become metabolically more vulnerable.What is perhaps most striking is that this
vulnerability extends directly to the heart itself. Research shows that
chemotherapy-induced muscle wasting can involve the myocardium — a phenomenon
known as cardiac wasting — which thins the ventricular wall, raises cardiac
stress, and can contribute to arrhythmias and heart failure independently of
the direct toxic effects of the drugs. Protecting skeletal muscle and
protecting the heart, it turns out, are not separate goals.
That is one reason why she sees rehabilitation as something far broader than
conventional exercise recovery. It must also include metabolic rebuilding, nutrient replenishment,
and resilience restoration.
One Size Does Not Fit All
Perhaps the most defining principle
in Dr. Hannoush’s philosophy is her insistence that no two patients should be treated as
biologically identical. “One size does not fit all,” she said
plainly. That statement applies not only to cancer treatment, but to what comes
after it.
This is where Dr. Hannoush’s
functional medicine training becomes most distinct. Standard cardio-oncology
guidelines — supported by major cardiac societies — focus on monitoring
ejection fraction and strain, managing blood pressure and cholesterol, and
initiating medications when cardiovascular risk is identified. These are
essential and evidence-based. But functional medicine, as practiced by Dr.
Hannoush, asks what lies beneath those numbers: What is this patient’s
individual metabolic reserve? How are they processing and eliminating the
chemical burden of treatment? What nutritional or hormonal imbalances are
amplifying their vulnerability? These questions, she believes, are just as
important as the clinical measurements and often go unasked.
In her view, survivorship care should be personalized using tools such as:
Nutrigenomics
Pharmacogenomics
Metabolomics
Advanced nutrient and
functional testing
Individualized detoxification
assessment
Cardiovascular and metabolic
monitoring
This is especially important because two patients can receive the same
therapy and emerge with dramatically different outcomes depending on their
baseline reserves, detoxification capacity, nutrient status, hormonal balance,
and metabolic health. “It’s not only about the outside toxins,” she noted.
“Chemotherapy is one of the toxins, of course. And you need to know how your
body is able to detoxify.”
That perspective — grounded in
functional medicine’s core principle of identifying root causes rather than
managing symptoms — broadens the survivorship conversation in an important way.
Rather than viewing side effects as unavoidable collateral damage, Dr. Hannoush
challenges clinicians to ask a more useful question: what can be measured, supported, and
personalized before the damage becomes permanent?
An Awareness Gap That Must
Be Closed
Dr. Hannoush also noted that the field still
carries significant blind spots — and that women are among those most affected
by them. Sex and racial differences in how cancer therapies damage the heart
remain poorly understood, and most foundational cardio-oncology research has
not been designed with these differences in mind. Women who have undergone
treatment for breast cancer — many of whom received anthracycline-based
chemotherapy, HER-2 inhibitors, aromatase inhibitors, or chest radiation
represent a large and growing population of survivors with elevated
cardiovascular risk. Yet the evidence base to guide their care remains incomplete. For readers of this publication,
that gap is not abstract: it is personal. Advocating for thorough
cardiovascular surveillance after cancer treatment is not overcaution: it is
self-knowledge
Despite the growing evidence in
support of cardio-oncology and personalized survivorship care, Dr. Hannoush
believes one of the greatest barriers is still lack of awareness. Many patients are never fully informed
about what to watch for after treatment. Some assume that once chemotherapy is
complete, the danger has passed. Others may not connect symptoms like fatigue,
exercise intolerance, palpitations, weight gain, or metabolic instability to
prior treatment exposure.
That silence, she suggests, is part of the problem. For now, she believes
the most realistic first step is not perfection—it is education. “Raising awareness
will be good as a start,” she said.
That awareness must extend to patients, caregivers, oncologists,
cardiologists, and the broader rehab community. Because if survivorship is
truly the goal, then medicine must stop measuring success only by tumor
shrinkage and begin asking a more complete question:
What did the treatment
save—and what did it cost? In that conversation, Dr. Hwaida
Hannoush offers a voice that is both scientifically grounded and clinically
humane. Her work reminds the medical world that surviving cancer should not
mean silently inheriting a second chronic disease. If precision medicine is truly the future, then survivorship care must
become just as precise.
Dr. Hwaida Hannoush is a board-certified cardiologist recognized for her work in women’s cardiovascular health, metabolic medicine, and healthy aging. She blends evidence-based cardiology with preventive and functional strategies to help patients protect heart health while improving long-term vitality. Her clinical focus explores how inflammation, insulin resistance, hormonal changes, stress, and lifestyle patterns influence cardiovascular risk—particularly in women and adults navigating midlife transitions. Known as both a physician and educator, Dr. Hannoush promotes early detection, personalized care, and multidisciplinary collaboration that integrates nutrition, endocrinology, and wellness principles to support stronger hearts and longer, healthier lives.
References
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., ... & ESC Scientific Document Group. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244
Camilli, M., Del Buono, M. G., Sanna, T., & Abbate, A. (2024). Anthracycline cardiotoxicity in adult cancer patients: JACC state-of-the-art review. JACC: CardioOncology, 6(5), 643–660. https://doi.org/10.1016/j.jaccao.2024.07.016
Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M. A., & Paraskevaidis, I. (2018). Cardio-oncology: A focus on cardiotoxicity. European Cardiology Review, 13(1), 64–69. https://doi.org/10.15420/ecr.2018:4:2
Dobson, R., Ghosh, A. K., Ky, B., Marwick, T., Stout, M., Harkness, A., & Senior, R. (2021). British Society of Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC: CardioOncology, 3(1), 1–16. https://doi.org/10.1016/j.jaccao.2021.01.011
Belger, C., Friedmann Angeli, J. P., & Bruns, D. R. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Biomedicine & Pharmacotherapy, 170, 115980. https://doi.org/10.1016/j.biopha.2023.115980
Qiu, Y., Gao, J., Chen, Y., & Wang, J. (2023). Anthracycline-induced cardiotoxicity: Mechanisms, monitoring, and prevention. Frontiers in Cardiovascular Medicine, 10, 1242596. https://doi.org/10.3389/fcvm.2023.1242596
Gent, D. G., Dent, S., & Lyon, A. R. (2023). The 2022 European Society of Cardiology cardio-oncology guidelines: Key messages for clinical practice. Cardiac Failure Review, 9, e18. https://doi.org/10.15420/cfr.2023.08
Bloom, M. W., Herrmann, J., Ky, B., & Lenihan, D. J. (2025). Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America. Journal of Cardiac Failure, 31(2), 145–170.
Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21–36. https://doi.org/10.1007/s10549-021-06205-8
Mecinaj, A., Gulati, G., Heck, S. L., & Omland, T. (2024). Impact of the ESC cardio-oncology guidelines biomarker criteria in anthracycline-treated breast cancer patients. JACC: CardioOncology, 6(1), 85–97.
Mallidi, J., Lenneman, C., & Herrmann, J. (2024). Management of cancer therapy-related cardiac dysfunction in clinical practice. American Journal of Cardiology, 214, 88–99.
Witteles, R. M., & Telli, M. L. (2022). ESC cardio-oncology guidelines: A triumph—but are we ready for implementation? JACC: CardioOncology, 4(4), 639–642. https://doi.org/10.1016/j.jaccao.2022.10.002
Understanding
the Stress Response
The
Cancer Diagnosis Itself Is a Stress Event
Imaging,
Insight, and Personalized Recovery
Dr. Bartlik notes that healing
requires safety. Patients who feel heard, supported, and empowered often do
better emotionally than those who feel dismissed or rushed. Compassionate
medicine lowers stress. Human connection matters.
